rosiglitazone has been researched along with Aura in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
Moreno, E; Negrín, MA; Vázquez-Polo, FJ | 1 |
Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
Deng, Y; Huang, Y; Li, R; Li, Y; Sun, H; Yang, J; Yu, X; Zhao, G | 1 |
4 other study(ies) available for rosiglitazone and Aura
Article | Year |
---|---|
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Objective Bayesian meta-analysis for sparse discrete data.
Topics: Bayes Theorem; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Epilepsy; Female; gamma-Aminobutyric Acid; Hormone Replacement Therapy; Humans; Meta-Analysis as Topic; Models, Statistical; Multicenter Studies as Topic; Pregnancy; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats.
Topics: Animals; Benzamides; Blotting, Western; Brain Injuries; CD40 Antigens; Central Nervous System Diseases; Enzyme-Linked Immunosorbent Assay; Epilepsy; Hippocampus; Immunohistochemistry; Inflammation; Lithium Compounds; Male; Pilocarpine; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; Rosiglitazone; Seizures; Status Epilepticus; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2008 |